BlackRock Fund Advisors recently announced the acquisition of new stake in CEL-SCI Corporation (AMEX:CVM). The institutional investor has increased its shareholding in the Healthcare company by 11.69% to 2.06 million shares with purchase of 0.22 million shares. This fresh investment now brings its stake to 5.46% valued currently at $30.67 million. In addition, The Vanguard Group, Inc. raised its holdings by 49126.0 to 1.58 million shares.
With over 0.5 million CEL-SCI Corporation (CVM) shares trading Friday and a closing price of $13.26 on the day, the dollar volume was approximately $6.64 million. The shares have shown a negative weekly performance of -1.04% and its price on 07/24/20 lost nearly -0.23%. Currently, there are 36.17M common shares owned by the public and among those 35.96M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for CVM have a consensus price objective of $21.00. The analysts have set the share’s price value over the next 12 months at a high of $23.00 and a low of $19.00 should the stock experience a downside. Incidentally, analysts’ outlook for the CEL-SCI Corporation stock is 2.00 for the next 12 months. The average price target is 42.35% above its last price level and an upside to the estimated low will see the stock gain 30.21% over that period. But an upside of 42.35% will see the stock hit the forecast high price target while mean target price for the stock is $21.00.
Insiders at the company have transacted a total of 29 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 27 of these insider trades were purchases, accounting for 33,623 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 16,000 shares.
The top 3 mutual fund holders in CEL-SCI Corporation are SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 2.07 million shares of the company’s stock, all valued at over $30.85 million. The company bought an additional 42398.0 shares recently to bring their total holdings to about 5.50% of the shares outstanding. iShares Russell 2000 ETF sold 17286.0 shares to bring its total holdings to over 0.68 million shares at a value of $10.14 million. iShares Russell 2000 ETF now owns shares totaling to 1.81% of the shares outstanding.
Shares of CEL-SCI Corporation (AMEX: CVM) opened at $13.25, down -$0.04 from a prior closing price of $13.29. However, the script later closed the day at $13.26, down -0.23%. The company’s stock has a 5-day price change of -1.04% and -12.65% over the past three months. CVM shares are trading 44.92% year to date (YTD), with the 12-month market performance up to 86.76% higher. It has a 12-month low price of $6.00 and touched a high of $18.00 over the same period. Currently, 0.5 million shares have been traded, compared to an average intraday trading volume of 829.05K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.63%, -6.24%, and 15.17% respectively.
Institutional ownership of CEL-SCI Corporation (AMEX: CVM) shares accounts for 26.20% of the company’s 36.17M shares outstanding. Mutual fund holders own 4.44%, while other institutional holders and individual stakeholders account for 8.83% and 16.93% respectively.
It has a market capitalization of $488.90M and a beta (3y monthly) value of 2.31. The earnings-per-share (ttm) stands at -$0.91. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.97% over the week and 7.02% over the month.
Analysts forecast that CEL-SCI Corporation (CVM) will achieve an EPS of -$0.15 for the current quarter, -$0.13 for the next quarter and -$0.47 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.19 while analysts give the company a high EPS estimate of -$0.11. Comparatively, EPS for the current quarter was -$0.37 a year ago. Earnings per share for the fiscal year are expected to increase by 62.10%, and 30.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate CEL-SCI Corporation (CVM) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the CVM, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 13, 2020, with the firm’s price target at $18. Dawson James coverage for the CEL-SCI Corporation (CVM) stock in a research note released on March 02, 2015 offered a Buy rating with a price target of $3.